Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Zetia

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Zetia was produced by Merck & Co. and Bayer.

Merck & Co's anacetrapib data fails to generate much excitement

Merck & Co's anacetrapib data fails to generate much excitement selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.

First round to Amgen in PCSK9 patent battle with Sanofi

First round to Amgen in PCSK9 patent battle with Sanofi For example, some payers are insisting that patients on statins try adding Merck &Co's selective cholesterol-absorption inhibitor Zetia (ezetimibe) before moving on to a PCSK9 inhibitor.

NICE backs Repatha but rejects cholesterol rival Praluent

NICE backs Repatha but rejects cholesterol rival Praluent Specifically, the UK watchdog said it was concerned that unlike Repatha Praluent has not been compared to the existing combination therapy of a statin plus MSD's Zetia (ezetimibe) in clinical

FDA panel rejects cardiovascular outcomes claim for Vytorin

FDA panel rejects cardiovascular outcomes claim for Vytorin It found a modest benefit with the addition of CETP inhibitor ezetimibe (Merck's Zetia) to the statin; 32.7% of the combination group suffered a major cardiovascular event over a ... Regardless of the outcome of the FDA's deliberations, Merck will face

PCSK9 inhibitors vastly over-priced, says ICER report

PCSK9 inhibitors vastly over-priced, says ICER report ICER's recommended price level would put Repatha and Praluent roughly in line with the price of Merck &Co's rival cholesterol drug Zetia (ezetimibe), which has been shown to be

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

DEMAND DIVERSITY REPORT 01: Exploring attitudes towards clinical research among people from different ethnic groups in the UK
This report reveals insights from the people themselves, and discusses the starting points for overcoming current challenges....
Why are new medicinal products denied reimbursement in France?
Many medicinal products looking to launch are rejected for reimbursement in France. A manufacturer must convince the Transparency Committee that their product is safe, effective and offers added value relative...
OPEN Health attend EB World Congress—building on momentum and strength in numbers for epidermolysis bullosa
Ben Speller shares his thoughts on the value of disease specific congresses...

Infographics